Cubist launches tender offer for Adolor
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals started its tender offer for all outstanding shares of the common stock of Adolor for $4.25 per share in cash, plus one nontransferable contingent payment right for up to $4.50 for each share tendered if certain regulatory approvals or commercialization milestones for Adolor's chronic opioid induced constipation (OIC) drug ADL5945 are achieved.